Health
FDA warns of potential serious eye risk with GLP-1 drugs, orders new warnings
The US Food and Drug Administration on 9 November 2026 warned of a potential risk of a serious eye condition associated with GLP-1 drugs used for weight loss and diabetes, and moved to require new risk communication, according to STAT News and Reuters.